<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56444">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371330</url>
  </required_header>
  <id_info>
    <org_study_id>TRF-1516</org_study_id>
    <nct_id>NCT02371330</nct_id>
  </id_info>
  <brief_title>The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study</brief_title>
  <acronym>Neo-HAT</acronym>
  <official_title>The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study - Neo-HAT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <brief_summary>
    <textblock>
      This is a prospective longitudinal study that evaluates Platelet Function Analyzer-100
      (PFA-100) CT-ADPs (closure time-ADP) and incidence of bleeding using the Neonatal Bleeding
      Assessment Tool - Neo-BAT in preterm neonates &lt;32 weeks gestational age or with a birth
      weight &lt;1500 grams and with different degrees of thrombocytopenia.

      The investigators hypothesized that PFA-100 CT-ADP, a global in vitro test of primary
      hemostasis, will be a better predictor of clinical bleeding in neonates than platelet count
      alone. A bleeding risk assessment marker could help physicians more accurately determine the
      risk/benefit ratio of platelet transfusions, guiding platelet transfusion decisions in
      neonates with thrombocytopenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neo-BAT score (Neo-BAT: Neonatal Bleeding Assessment Tool)</measure>
    <time_frame>study period: 5 days</time_frame>
    <description>The NeoBAT is a simple, reliable and objective tool for the standardized assessment of bleeding in neonates, which was developed by an international team of experts based on the World Health Organization bleeding score for adults.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of thrombotic events</measure>
    <time_frame>up to post-conceptional age 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Thrombocytopenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the Neonatal Intensive Care Unit who are &lt;32 weeks gestation or with
        a birth weight &lt;1500 grams.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt;32 weeks gestation or with a birth weight &lt;1500 grams;

          -  Have confirmed moderate-to-severe thrombocytopenia, defined as a platelet count
             &lt;100x109/L;

          -  Have a parent/guardian willing to comply with the protocol and provide written
             informed consent.

        Exclusion Criteria:

          -  Are not expected to survive by the Attending Neonatologist;

          -  Are thought to have a congenital thrombocytopenia or platelet dysfunction, based on
             family history or clinical presentation (e.g. associated congenital malformations,
             platelet morphology);

          -  Have a major chromosomal anomaly such as Trisomy 13, 18, or 21.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emoke Deschmann, M.D., M.M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Women's and Children's Health, Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emoke Deschmann, M.D.,M.M.Sc.</last_name>
    <phone>+46-70-001-7401</phone>
    <email>emoke.deschmann@karolinska.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pediatrics, Levine Children's Hospital, Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew A. Saxonhouse, M.D.</last_name>
      <email>msaxonhouse@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren Children's Hospital, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emoke Deschmann, M.D., M.M.Sc.</last_name>
      <phone>+46 70 001 7401</phone>
      <email>emoke.deschmann@karolinska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Deschmann E, Sola-Visner M, Saxonhouse MA. Primary hemostasis in neonates with thrombocytopenia. J Pediatr. 2014 Jan;164(1):167-72. doi: 10.1016/j.jpeds.2013.08.037. Epub 2013 Oct 3.</citation>
    <PMID>24094764</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 29, 2016</lastchanged_date>
  <firstreceived_date>February 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Emoke Deschmann</investigator_full_name>
    <investigator_title>M.D., M.M.Sc., Attending Neonatologist</investigator_title>
  </responsible_party>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Neonate</keyword>
  <keyword>PFA-100</keyword>
  <keyword>Neo-BAT</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
